These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36466201)

  • 1. Prevention and management of hearing loss in patients receiving ototoxic medications.
    Lindeborg MM; Jung DH; Chan DK; Mitnick CD
    Bull World Health Organ; 2022 Dec; 100(12):789-796A. PubMed ID: 36466201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line injectable induced ototoxicity in drug resistant tuberculosis: A systematic review of Indian studies.
    Sarin R; Behera D; Khanna A; Singh V; Narang P; Deepak TS
    Indian J Tuberc; 2019 Apr; 66(2):279-287. PubMed ID: 31151497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of aminoglycoside-induced hearing loss in drug-resistant tuberculosis patients: A systematic review.
    Dillard LK; Martinez RX; Perez LL; Fullerton AM; Chadha S; McMahon CM
    J Infect; 2021 Jul; 83(1):27-36. PubMed ID: 34015383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal community-based ototoxicity monitoring programme and treatment effects for drug-resistant tuberculosis treatment, Western Cape.
    Stevenson LJ; Biagio-de Jager L; Graham MA; Swanepoel W
    S Afr J Commun Disord; 2022 Mar; 69(1):e1-e13. PubMed ID: 35384675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant Tuberculosis.
    Arnold A; Cooke GS; Kon OM; Dedicoat M; Lipman M; Loyse A; Chis Ster I; Harrison TS
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.
    Konrad-Martin D; Poling GL; Garinis AC; Ortiz CE; Hopper J; O'Connell Bennett K; Dille MF
    Int J Audiol; 2018 Sep; 57(sup4):S3-S18. PubMed ID: 29157038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global burden of ototoxic hearing loss associated with platinum-based cancer treatment: A systematic review and meta-analysis.
    Dillard LK; Lopez-Perez L; Martinez RX; Fullerton AM; Chadha S; McMahon CM
    Cancer Epidemiol; 2022 Aug; 79():102203. PubMed ID: 35724557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ototoxicity in childhood: Recommendations of the CODEPEH (Commission for the Early Detection of Childhood Hearing Loss) for prevention and early diagnosis.
    Núñez-Batalla F; Jáudenes-Casaubón C; Sequí-Canet JM; Vivanco-Allende A; Zubicaray-Ugarteche J
    Acta Otorrinolaringol Esp (Engl Ed); 2022; 73(4):255-265. PubMed ID: 35872300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Acetyl-L-cysteine Affects Ototoxicity Evoked by Amikacin and Furosemide Either Alone or in Combination in a Mouse Model of Hearing Threshold Decrease.
    Zadrożniak M; Szymański M; Łuszczki JJ
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study.
    Shibeshi W; Sheth AN; Admasu A; Berha AB; Negash Z; Yimer G
    BMC Pharmacol Toxicol; 2019 May; 20(1):31. PubMed ID: 31122273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse outcome pathway for aminoglycoside ototoxicity in drug-resistant tuberculosis treatment.
    Hong H; Dooley KE; Starbird LE; Francis HW; Farley JE
    Arch Toxicol; 2019 May; 93(5):1385-1399. PubMed ID: 30963202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in VigiBase® reporting of aminoglycoside and capreomycin-suspected ototoxicity during tuberculosis treatment.
    Sagwa EL; Souverein PC; Ribeiro I; Leufkens HG; Mantel-Teeuwisse AK
    Pharmacoepidemiol Drug Saf; 2017 Jan; 26(1):1-8. PubMed ID: 27868278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity among multidrug-resistant TB patients: a systematic review and meta-analysis.
    Wrohan I; Redwood L; Ho J; Velen K; Fox GJ
    Int J Tuberc Lung Dis; 2021 Jan; 25(1):23-30. PubMed ID: 33384041
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravenously delivered aminoglycoside antibiotics, tobramycin and amikacin, are not ototoxic in mice.
    Ogier JM; Lockhart PJ; Burt RA
    Hear Res; 2020 Feb; 386():107870. PubMed ID: 31864009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice.
    Sturdy A; Goodman A; José RJ; Loyse A; O'Donoghue M; Kon OM; Dedicoat MJ; Harrison TS; John L; Lipman M; Cooke GS
    J Antimicrob Chemother; 2011 Aug; 66(8):1815-20. PubMed ID: 21642291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ototoxic hearing loss from antimalarials: A systematic narrative review.
    Dillard LK; Fullerton AM; McMahon CM
    Travel Med Infect Dis; 2021; 43():102117. PubMed ID: 34129960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High rifampicin-resistant TB cure rates and prevention of severe ototoxicity after replacing the injectable by linezolid in early stage of hearing loss.
    Souleymane MB; Piubello A; Lawan IM; Hassane-Harouna S; Assao-Neino MM; Soumana A; Hamidou-Harouna Z; Gagara-Issoufou A; Ortuño-Gutiérrez N; Roggi A; Schwoebel V; Mamadou S; Lynen L; De Jong B; Van Deun A; Decroo T
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32703777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The safety and tolerability of the second-line injectable antituberculosis drugs in children.
    Garcia-Prats AJ; Schaaf HS; Hesseling AC
    Expert Opin Drug Saf; 2016 Nov; 15(11):1491-1500. PubMed ID: 27548570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Ototoxicity Grading System Within a Mobile App (OtoCalc) for a Resource-Limited Setting to Guide Grading and Management of Drug-Induced Hearing Loss in Patients With Drug-Resistant Tuberculosis: Prospective, Cross-Sectional Case Series.
    Hollander C; Joubert K; Schellack N
    JMIR Mhealth Uhealth; 2020 Jan; 8(1):e14036. PubMed ID: 31934875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.